Agenda

This session will delve into the details of the topics covered in the keynote session, with a focus on what kind of innovation the industry-standard CRM, which facilitates communication between pharmaceutical companies and medical professionals, will bring in the future.

Previously, we had no established methodology for referencing customer information, including that of key opinion leaders, requiring us to rely on referencing various facilities, conferences, and literature search sites that were based on individuals' knowledge and experience. Because the quality of this method was highly-dependent on the competence of individuals, it raised concerns over efficiency and the comprehensiveness of information. In response, we tried to solve the issue by introducing Veeva Link, but found that it took some innovative ideas to promote its widespread use at our company. This session will present these innovative ideas in the hopes of providing valuable insight to attendees who may be considering the service.

It is clear that human impact of Covid-19 is irreversible eversible in many ways, but also the environment surrounding HCPs is rapidly changing and will continue to evolve. Under such circumstances, pharmaceutical companies are needed to be agile and constantly redefine to adopt to continuously changing HCP needs. To that end, we will discuss on what the future state of marketing should be and how to promote change to realize it, from speaker who currently oversees multiple brand teams in the oncology field.

With the rapid shift in the pharmaceutical industry to providing information online, it has become even more important to adopt omnichannel strategies that integrate multiple channels.

This session will introduce examples of optimal omnichannel-focused solutions that are tailored to the behavior of healthcare professionals while providing examples of real-world initiatives as a point of reference.

With the help of Generative AI, pharmaceutical firms can optimize their scientific exchange by examining consumer behavior and preferences and communicate the right message to the right audience. In this session we will explore how Generative AI in Sales and Medical and marketing can advance customer journey and drive field force productivity.

Astellas began implementing Veeva CRM in 2022, and in 2023, we made the decision to adopt Veeva Events Management as global standard platform. The purpose is to enhance our event management process and make effective use of event data. During this session, we will present Astellas's Events Management project, highlighting the obstacles faced, key factors contributing to success, and our future plans and expectations.

Medicine is constantly evolving, resulting in an array of treatment options. How can we, as pharmaceutical companies, respond to the various questions that arise in doctors' daily practices?
We must drive the evolution of an engagement model capable of quickly delivering the information physicians need, when they need it. We must also be prepared for the changes that will result from doctors' work-style reforms.
This session will explore how we can support a new engagement model through the Engage platform, explained through specific use cases. It will also provide insight into how Veeva's engagement model will evolve in the future while incorporating information from the product roadmap.

In the development of new drugs by pharmaceutical companies, as more drugs with novel mechanisms of action are being developed, there is a growing demand for medically and scientifically information among healthcare professionals, including Key Opinion Leaders (KOLs). Additionally, in order to meet the diverse needs of healthcare professionals, it is necessary to enhance customer engagement through omni-channel approaches. However, many pharmaceutical companies are facing dilemmas and challenges in terms of collaboration between their medical departments and other departments, as well as driving transformation.

Through a panel discussion with members of the medical department, it provides an opportunity to engage with the medical department and delve into their efforts to address challenges and drive change.

Hear about the global trends for content in the pharma industry and how these compare with Japan’s unique challenges and opportunities.
Learn how Vault PromoMats innovations in Modular Content, DAM and Claims are enabling the industry to evolve their content operations

This session features a panel discussion based on industry conditions revealed by doctor questionnaires and interviews on doctors' work-style reforms scheduled for April 2024, as well as changes in the use of each channel. During the discussion, panel guests will debate the issues and challenges that pharmaceutical companies face, the best way to deliver information via various channels, and other important issues.

Session Information Coming Soon.

Pharmaceutical companies are under increasing pressure to create and leverage a wide range of content as customers' information needs become more personalized and communication channels diversify. One possible solution is the modular content approach, which is gaining popularity in Europe and the United States and is expected to be adopted in Japan. To prepare for such a future, it is critical to increase the efficiency of current content production and make it more effective. From the perspective of introducing DAM and promoting the effective use of content, this session introduces real-world examples of using Veeva along with efforts at Eli Lilly.